Healthcare Industry News: Neoprobe
News Release - December 3, 2007
Neoprobe's Lymphoseek Issued Japanese Patent
DUBLIN, Ohio--(HSMN NewsFeed)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that notification was recently received by the University of California, San Diego (UCSD) regarding the allowance of the first patent covering Lymphoseek® in Japan. Neoprobe holds the exclusive rights to Lymphoseek under license from UCSD for use in diagnostic applications such as lymphatic mapping as well as in ultrasound and optical imaging. Lymphoseek is also covered by patents previously issued to UCSD in June of 2002 (U.S. patent 6,419,990) and in the European Union in November 2005.Lymphoseek (Technetium Tc99m DTPA-mannosyl-dextran) is a proprietary radioactive lymphatic mapping targeting agent being developed by Neoprobe for use with handheld gamma detection devices, such as Neoprobe’s neo2000® system. After achieving positive efficacy results in recently completed Phase 2 multicenter clinical trials for Lymphoseek, Neoprobe is now moving forward with preparations for two Phase 3 clinical trials; one in breast cancer and one in melanoma.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.Neoprobe.com
Source: Neoprobe
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
